Team:RAMNOTIREN CALGARY/HumanPractices

From 2014hs.igem.org

(Difference between revisions)
 
(17 intermediate revisions not shown)
Line 19: Line 19:
h3{
h3{
font-size: 25.5px;
font-size: 25.5px;
-
}
+
}  
-
 
+
-
p {
+
-
text-indent:50px;
+
-
}   
+
#content {  
#content {  
Line 95: Line 91:
}
}
-
#footer {
 
-
border: none;
 
-
width: 850px;
 
-
margin: 0 auto;
 
-
padding: 0;
 
-
}
 
.firstHeading {  
.firstHeading {  
Line 115: Line 105:
}
}
-
.printfooter {
 
-
display: none;
 
-
}
 
-
 
-
#footer ul {
 
-
margin: 0;
 
-
padding: 0;
 
-
}
 
-
 
-
#footer ul li {
 
-
margin-top: 0;
 
-
margin-bottom: 0;
 
-
margin-left: 10px;
 
-
margin-right: 10px;
 
-
padding: 0;
 
-
}
 
#search-controls {  
#search-controls {  
Line 158: Line 132:
}
}
-
.plus {
+
                h7{
-
        display: inline-block;
+
                        font-size: 25.5px;
-
        -webkit-transition: 1s ease-in-out;
+
                        font-family: arial, verdana;
-
        -moz-transition: 1s ease-in-out;
+
                        color: #FFF;
-
        -o-transition: 1s ease-in-out;
+
                }
-
    }
+
 
-
     
+
                #sidebar{
-
    .menu:hover .plus {
+
                position: relative;
-
        -webkit-transform: rotate(1000deg);
+
                top: 0px;
-
        -moz-transform: rotate(1000deg);
+
                left: -75px;              
-
        -o-transform: rotate(1000deg);
+
                width: 300px;
-
    }
+
                padding: 10px;
 +
                }
 +
 
 +
                #sidebar ul li{
 +
                        list-style-type: none;
 +
                        padding: 2px 0px 2px 0px;
 +
                }
 +
 
 +
                #sidebar ul li a{
 +
                        color: #FFF;
 +
                        font-family: arial, verdana, cambria;
 +
                        /*ffc750 yellow for hover color*/
 +
                                               
 +
                }
 +
 
 +
                #sidebar a{
 +
                        text-decoration: none;
 +
                }
 +
 
 +
                #sidebar a:hover{
 +
                        color: #ffc750;
 +
                }
 +
 
 +
                #list{
 +
                  position: relative;
 +
                  top: -220px;
 +
 
 +
                }
 +
 
 +
                #listt{
 +
                        padding-bottom: 20px;
 +
                       
 +
                }
 +
 
 +
                #hpprologue{
 +
                  position: relative;
 +
                  top: -429px;
 +
                  left: 178px;
 +
                  background-color: #E6E6E6;
 +
                  font-family: arial, verdana;
 +
                  border-radius: 3px;
 +
                  width: 680px;
 +
                  padding: 40px 40px 20px 40px;
 +
                }
 +
 
 +
                #hpprologue2{
 +
                  position: relative;
 +
                  top:-802px;
 +
                  left: 468px;
 +
                  background-color: #E6E6E6;
 +
                  font-family: arial, verdana;
 +
                  border-radius: 3px;
 +
                  width: 393px;
 +
                  height: 315px;
 +
                  padding: 40px 40px 20px 40px;
 +
                }
 +
 
 +
                #pietable{
 +
                  position: relative;
 +
                  top:-424px;
 +
                  left:-10px;
 +
                  float: center;
 +
                  background-color: transparent;
 +
                }
 +
 
Line 219: Line 257:
         setInterval( "slider()", 5000 );
         setInterval( "slider()", 5000 );
     });
     });
 +
/*back to top JS start */
 +
 +
    $(document).ready(function () {
 +
 +
    $(window).scroll(function () {
 +
        if ($(this).scrollTop() > 100) {
 +
            $('.scrollup').fadeIn();
 +
        } else {
 +
            $('.scrollup').fadeOut();
 +
        }
 +
    });
 +
 +
    $('.scrollup').click(function () {
 +
        $("html, body").animate({
 +
            scrollTop: 0
 +
        }, 600);
 +
        return false;
 +
    });
 +
 +
});
 +
 +
//back to top js script end
   
   
</script>
</script>
<script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.2/jquery.js"></script>
<script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.2/jquery.js"></script>
 +
 +
<script type="text/javascript" src https://2014hs.igem.org/wiki/index.php?title=2014hs.igem.org:Copyrights&action=edit&redlink=1="https://2014hs.igem.org/common/jquery-latest.min.js"></script>
 +
 +
<script type='text/javascript' src='http://ajax.googleapis.com/ajax/libs/jquery/1.3.2/jquery.min.js?ver=1.3.2'></script>
</head>
</head>
Line 260: Line 324:
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎" id="homelink">Home</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎" id="homelink">Home</a></li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Team" id="teamlink">Team</a>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members" id="teamlink">Team</a>
<ul>
<ul>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li>
-
<li><a href="https://igem.org/Team.cgi" target="_blank">Official Profile</a></li>
+
<li><a href="https://igem.org/Team.cgi?id=1295" target="_blank">Official Profile</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
</ul>
</ul>
</li>
</li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project" id="projectlink">Project </a>
+
                                  <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink">Project </a>
<ul>
<ul>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Content</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
 +
                                                <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
Line 281: Line 346:
<li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a></li>
<li><a class="drop" href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Notebook" id="notebooklink">Notebook</a></li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Sponsors" id="sponsorslink">Sponsors</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Protocols" id="protocollink">Protocols</a></li>
<li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li>
<li><a href="https://2014hs.igem.org" target="_blank">iGEM</a></li>
Line 287: Line 352:
</div>
</div>
</header>
</header>
 +
 +
<div id="sidebar">
 +
    <img id="image" src="https://static.igem.org/mediawiki/2014hs/6/68/Sidebarimgft.jpg"/>
 +
  <ul id="list">
 +
    <div id="listt">
 +
      <h7>PROJECT</h7>
 +
    </div>
 +
      <li> <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li>
 +
      <li> <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
 +
      <li> <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li>
 +
      <li> <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
 +
      <li> <a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>               
 +
    </ul>
 +
</div>
 +
 +
<div id="hpprologue">
 +
  <p>For the human practices portion of our project we put up a survey online, getting 136 people to respond to the questions listed below: <br>
 +
  1. Have you or someone close to you ever been affected by cancer?<br>
 +
  2. Would you be comfortable having bacteria injected into your bloodstream if it could potentially treat or cure cancer?<br>
 +
  3. Would you still want to undergo this treatment if it meant suffering side effects such as fatigue and/or flu-like symptoms (i.e. nausea, vomiting, diarrhea, etc.)?<br>
 +
  4. Assuming similar success rates, would you prefer to undergo chemotherapy, or this bacterial treatment option?<br>
 +
  5. Would you choose this treatment option if the duration of the treatment was the same as that of traditional forms of treatment, such as chemotherapy?<br>
 +
  6. If this form of treatment took twice as long as traditional treatment options, but with higher success rates, would you still opt for this treatment?<br>
 +
  7. During treatment, would you be comfortable limiting/cutting out all physical activity?<br>
 +
  8. Would you support your tax dollars going towards developing this type of treatment?<br>
 +
  9. Identify your age range: 14-18, 19-24, 25-32, 41-51, 52+ </p><br><br>
 +
 +
  <p>We turned our survey information into pie charts and the results are as follows:</p><br>
 +
</div>
 +
 +
  <table id="pietable">
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/e/e6/PCHCART1.jpg" width="471px" height="377px"/></td>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/e/e4/PCHCART2.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/3/3d/PCHCART3.jpg" width="471px" height="377px"/></td>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/0/0b/PCHCART4.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/5/55/PCHCART5.jpg" width="471px" height="377px"/></td>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/1/1c/PCHCART6.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/3/3f/PCHCART7.jpg" width="471px" height="377px"/></td>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/e/e8/PCHCART8.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/9/97/PCHCART9.jpg" width="471px" height="377px"/></td>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/6/65/PCHCART10.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
    <tr>
 +
      <td><img src="https://static.igem.org/mediawiki/2014hs/9/98/PCHCART11.jpg" width="471px" height="377px"/></td>
 +
    </tr>
 +
 +
  </table>
 +
 +
<div id="hpprologue2">
 +
  <p>We found that openness for the funding for this type of project had an overwhelming 95% approval. The majority of the people who’d taken the survey were open to trying our type of treatment, especially if it proved to be more effective than chemotherapy.
 +
  The one major problem most people had, related to the function of the lactic acid promoter in the body. People were concerned about how much physical activity they would have to limit for what periods of time. <!--DETAILS--> </p>
 +
</div>
 +
        <article>
 +
                    <a href="http://www.google.com" target="test" class="scrollup">Scroll</a>
 +
        </article>
</body>
</body>
</html>
</html>

Latest revision as of 08:47, 20 June 2014

For the human practices portion of our project we put up a survey online, getting 136 people to respond to the questions listed below:
1. Have you or someone close to you ever been affected by cancer?
2. Would you be comfortable having bacteria injected into your bloodstream if it could potentially treat or cure cancer?
3. Would you still want to undergo this treatment if it meant suffering side effects such as fatigue and/or flu-like symptoms (i.e. nausea, vomiting, diarrhea, etc.)?
4. Assuming similar success rates, would you prefer to undergo chemotherapy, or this bacterial treatment option?
5. Would you choose this treatment option if the duration of the treatment was the same as that of traditional forms of treatment, such as chemotherapy?
6. If this form of treatment took twice as long as traditional treatment options, but with higher success rates, would you still opt for this treatment?
7. During treatment, would you be comfortable limiting/cutting out all physical activity?
8. Would you support your tax dollars going towards developing this type of treatment?
9. Identify your age range: 14-18, 19-24, 25-32, 41-51, 52+



We turned our survey information into pie charts and the results are as follows:


We found that openness for the funding for this type of project had an overwhelming 95% approval. The majority of the people who’d taken the survey were open to trying our type of treatment, especially if it proved to be more effective than chemotherapy. The one major problem most people had, related to the function of the lactic acid promoter in the body. People were concerned about how much physical activity they would have to limit for what periods of time.